Core Insights - Evaxion A/S announced unprecedented two-year clinical efficacy data for its personalized cancer vaccine EVX-01 in patients with advanced melanoma, showcasing a significant potential as a new treatment option [1][6] Clinical Efficacy Data - The two-year phase 2 data revealed an Objective Response Rate (ORR) of 75%, with 12 out of 16 patients showing objective clinical responses, including four achieving complete response [2][11] - A durable clinical benefit was noted, with 92% of patients still responding at the 24-month follow-up and no relapses observed [2][11] - 54% of patients experienced a deepened response during treatment, transitioning from stable disease or partial response to partial or complete response [3][9] Immune Response and Safety - EVX-01 induced an immune response in all patients, with 81% of targeted neoantigens generating potent specific T-cell responses, indicating high immunogenicity [4][11] - The treatment was confirmed to be well-tolerated, aligning with the favorable safety profile observed in the phase 1 study [5][11] Future Developments - The trial has been extended for an additional year, during which participants will receive EVX-01 as monotherapy, with data from this extension expected to be presented in 2026 [14] - Evaxion plans to discuss the data with stakeholders and potential partners, emphasizing the need for partnerships in further clinical development [6][12] Presentation and Engagement - Data was presented at the European Society for Medical Oncology (ESMO) Congress 2025, with opportunities for discussions at the conference [8][11] - An online webinar featuring key opinion leader Professor Muhammad Adnan Khattak is scheduled for October 22, 2025, to discuss the two-year phase 2 data and challenges in treating advanced melanoma [12]

Core Insights - BriaCell Therapeutics Corp. has received a non-dilutive research grant of $2,054,651 from the National Cancer Institute to advance its Bria-PROS+ immunotherapy for prostate cancer [1][7] - The grant will support the completion of manufacturing for Bria-PROS+ and fund a Phase 1/2a clinical trial in patients with advanced prostate cancer [2][7] - The Bria-OTS+ platform aims to simplify and reduce the costs associated with traditional personalized cancer treatments, addressing an urgent unmet medical need in cancer care [4][7] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [4] - The company is advancing its personalized off-the-shelf immunotherapy approach, which is expected to significantly improve personalized cancer treatment [4][7] Clinical Study Insights - Dr. William Oh, the Principal Investigator for the upcoming clinical study, emphasized the need for effective treatments for metastatic hormone-sensitive prostate cancer, highlighting the urgency of the medical need [3] - The Phase 1/2a clinical trial will investigate the efficacy of Bria-PROS+ in patients suffering from advanced prostate cancer [2][3]

Core Insights - BriaCell Therapeutics Corp. has received a research grant of $2,054,651 from the National Cancer Institute to advance its Bria-PROS+ immunotherapy for prostate cancer [1][7] - The grant will support the completion of manufacturing for Bria-PROS+ and fund a Phase 1/2a clinical trial in patients with advanced prostate cancer [2][7] - The Bria-OTS+ platform aims to simplify and expedite personalized cancer treatments, addressing significant unmet medical needs in cancer care [4][7] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [4] - The company is advancing its Bria-PROS+ platform, which is designed to provide off-the-shelf personalized immunotherapy solutions [4][7] Clinical Development - The upcoming Phase 1/2a clinical trial will investigate the efficacy of Bria-PROS+ in patients with metastatic prostate cancer, a condition with limited treatment options [3][7] - Dr. William Oh from Yale Cancer Center is the Principal Investigator for the clinical study, highlighting the urgency of addressing unmet medical needs in this area [3][7]